Results for derived translation from Italian to Finnish

core spc for human plasma derived
core spc for human plasma derived

for guidance on plasma-derived medicinal
for guidance on plasma- derived medicinal

note for guidance on plasma-derived medicinal products
note for guidance on plasma- derived medicinal products

safety and supply of plasma- derived medicinal products
safety and supply of plasma - derived medicinal products

clinical investigation of plasma derived factor viii and ix products
clinical investigation of plasma derived factor viii and ix products

addendum to note for guidance on plasma-derived medicinal products
addendum to note for guidance on plasma- derived medicinal products

core spc for human plasma derived and recombinant coagulation factor ix products
core spc for human plasma derived and recombinant coagulation factor ix products

titolo del documento note for guidance on plasma-derived medicinal products
asiakirjan nimi note for guidance on plasma- derived medicinal products

immunoglobulin for intravenous administration (ivig) core spc for human plasma derived and
immunoglobulin for intravenous administration (ivig) core spc for human plasma derived and

investigation of human plasma derived factor viii and ix products note for guidance on the clinical
investigation of human plasma derived factor viii and ix products note for guidance on the clinical

the expiry date of products incorporating plasma-derived products as stabilisers or excipients:
the expiry date of products incorporating plasma- derived products as stabilisers or excipients:

core spc for human plasma derived antithrombin note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use
core spc for human plasma derived antithrombin note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use

documento concettuale concept paper on gene therapy concept paper on the development of a cpmp guideline on comparability of biotechnology-derived products
selvitys concept paper on gene therapy concept paper on the development of a cpmp guideline on comparability of biotechnology- derived products

titolo del documento note for guidance on the clinical investigation of plasma derived fibrin sealants note for guidance on the clinical investigation of von willebrand factor warning on transmissible agents for patient leaflets and spcs core spc for plasma derived fibrin sealants
asiakirjan nimi note for guidance on the clinical investigation of plasma derived fibrin sealants note for guidance on the clinical investigation of von willebrand factor warning on transmissible agents for patient leaflets and spcs core spc for plasma derived fibrin sealants

contribution to part s.2.3 of the structure of the dossier for applications for marketing authorisation – control of starting materials for the production of plasma-derived medicinal products
contribution to part s. 2. 3 of the structure of the dossier for applications for marketing authorisation – control of starting materials for the production of plasma- derived medicinal products

core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti-d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular